• AI
  • Molecular Imaging
  • CT
  • X-Ray
  • Ultrasound
  • MRI
  • Facility Management
  • Mammography

Hologic finalizes acquisition of DRC

Article

Hologic finalizes acquisition of DRCBone densitometer firm Hologic has completed its purchase of Direct Radiography from SDI Holding, the parent company of Agfa subsidiary Sterling Diagnostic Imaging. The deal was valued at about $20 million,

Hologic finalizes acquisition of DRC

Bone densitometer firm Hologic has completed its purchase of Direct Radiography from SDI Holding, the parent company of Agfa subsidiary Sterling Diagnostic Imaging. The deal was valued at about $20 million, consisting of $7 million in cash and around 1.9 million shares of Hologic common stock. The purchase amount decreased sharply from the initial agreement, which was valued at about $30 million.

Hologic was able to get some price concessions in exchange for a speedy closing, said David Ellenbogen, Hologic chairman and CEO.

As a result of the acquisition, Hologic receives about 90 employees, a 168,000-square-foot research, development, manufacturing, and administrative site in Newark, DE, and 26 U.S. patents, as well as a number of foreign ones.

Hologic plans to market DRC’s DirectRay digital radiography technology via a number of channels, including OEM opportunities. Discussions with several potential OEM clients are under way, Ellenbogen said.

The company also will participate in the retrofit sector, equipping recently purchased traditional x-ray rooms with its DirectRay detectors to pave the way for PACS, he said. In addition to the firm’s first retrofit site at Brooke Army Medical Center in Fort Sam Houston, TX, (PNN 2/99), DRC has installed a retrofit at an undisclosed location.

Finally, Bedford, MA-based Hologic will continue DRC’s direct sales efforts with its traditional iiRAD systems. In future development plans, Hologic expects to bring DirectRay technology suitable for fluoroscopy and mammography applications to market. Commercialization of these products would not occur for at least a year, however, Ellenbogen said.

Recent Videos
Emerging Research at SNMMI Examines 18F-flotufolastat in Managing Primary and Recurrent Prostate Cancer
Could Pluvicto Have a Role in Taxane-Naïve mCRPC?: An Interview with Oliver Sartor, MD
New SNMMI President Cathy Cutler, PhD, Discusses Current Challenges and Goals for Nuclear Medicine
Where the USPSTF Breast Cancer Screening Recommendations Fall Short: An Interview with Stacy Smith-Foley, MD
A Closer Look at MRI-Guided Transurethral Ultrasound Ablation for Intermediate Risk Prostate Cancer
Improving the Quality of Breast MRI Acquisition and Processing
Can Fiber Optic RealShape (FORS) Technology Provide a Viable Alternative to X-Rays for Aortic Procedures?
Does Initial CCTA Provide the Best Assessment of Stable Chest Pain?
Making the Case for Intravascular Ultrasound Use in Peripheral Vascular Interventions
Can Diffusion Microstructural Imaging Provide Insights into Long Covid Beyond Conventional MRI?
Related Content
© 2024 MJH Life Sciences

All rights reserved.